CS-Keys, Inc., founded in Indianapolis, Indiana, is a private biotechnology company dedicated to discovering and developing cancer-associated biomarkers through proteomics. The company's core mission is to innovate cancer diagnostics by creating novel tests based on cancer-associated isoforms of PCNA antibody technology. Their primary product offerings include advanced cancer diagnostic tests and immunohistochemistry stains for examining tissue biopsies where cancer is suspected, targeting the healthcare and medical research markets.
Notable affiliated individuals and investors have not been specified. However, CS-Keys has achieved significant milestones in the field of cancer diagnostics, contributing to early detection and improved patient outcomes. The company's impact lies in its ability to enhance diagnostic accuracy, potentially leading to more effective treatment plans and better survival rates for cancer patients.
